TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17761004

Group type: EXPERIMENTAL
Intervention: Physiotherapy program including shoulder joint and spinal mobilisation, soft tissue massage, postural taping, and home exercises for scapular control, posture and rotator cuff strengthening.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo group receiving inactive ultrasound and gentle application of an inert gel over the shoulder region.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Physiotherapy program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 200
Study: 15269312

Group type: EXPERIMENTAL
Intervention: Higher PEEP (mean 13.2+/‐3.5 cm of water)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Lower PEEP (mean 8.3+/‐3.2 cm of water)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Higher PEEP
Number of subjects: 549

Group type: COMPARATOR
Intervention: Lower PEEP
Number of subjects: 549
Study: 11139315

Group type: EXPERIMENTAL
Intervention: 5th edition TNM classification
Number of subjects: 633

Group type: COMPARATOR
Intervention: 4th edition TNM classification
Number of subjects: 633
Study: 9647940

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (VIAGRA)
Number of subjects: 4274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4274
Study: 8073240

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmaceutical treatments
Number of subjects: 0
Study: 2799271

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Ferric-aluminum-fluoride solution (FeAlF)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 189
Study: 1107648

Group type: EXPERIMENTAL
Intervention: Ocusert drug delivery system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pilocarpine-eyedrops
Number of subjects: 0
Study: 31090673

Group type: EXPERIMENTAL
Intervention: Acute aspirin (81 mg; single-dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chronic aspirin (81 mg; 14 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (acute)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (chronic)
Number of subjects: 24
Study: 27986983

Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D3
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 25650370

Group type: EXPERIMENTAL
Intervention: Perhexiline 200 mg for 1 month
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 50
Study: 24824408

Group type: EXPERIMENTAL
Intervention: CAG repeat length
Number of subjects: 1539
Study: 23250319

Group type: EXPERIMENTAL
Intervention: Home oxygen therapy
Number of subjects: 194
Study: 19382032

Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day peroral iron for 2 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 20
Study: 17998507

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 716

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Ranibizumab (both doses)
Number of subjects: 716
Study: 16003697

Group type: EXPERIMENTAL
Intervention: Initial ST-segment deviation
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Formula derived from initial ECG measurements
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Study population characteristics
Number of subjects: 69
Study: 12418722

Group type: EXPERIMENTAL
Intervention: 4.0% w/v betaine with 1% SLS
Number of subjects: 25

Group type: COMPARATOR
Intervention: 2% SLS
Number of subjects: 25

Group type: COMPARATOR
Intervention: 2% CAPB
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 4.0% w/v betaine with 2% CAPB
Number of subjects: 25
Study: 10353377

Group type: EXPERIMENTAL
Intervention: Alcohol condition
Number of subjects: 36

Group type: COMPARATOR
Intervention: No-alcohol condition
Number of subjects: 36
Study: 8951190

Group type: EXPERIMENTAL
Intervention: Proguanil hydrochloride and atovaquone
Number of subjects: 370
Study: 1766047

Group type: EXPERIMENTAL
Intervention: MCT/LCT emulsion
Number of subjects: 14

Group type: COMPARATOR
Intervention: LCT emulsion
Number of subjects: 14
Study: 7051944

Group type: EXPERIMENTAL
Intervention: Lugol's iodine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 31811950

Group type: EXPERIMENTAL
Intervention: Genetic variant rs76766811 in African Americans
Number of subjects: 4974

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4974
Study: 30654789

Group type: EXPERIMENTAL
Intervention: BMI assessment
Number of subjects: 27955

Group type: EXPERIMENTAL
Intervention: Physical fitness tests (50-m sprint run, sit-and-reach, standing-broad jump, sit-ups, pull-ups, 1000 m/boy or 800 m/girl distance run)
Number of subjects: 27955

Group type: COMPARATOR
Intervention: Socio-economic status (SES) impact on fitness performance
Number of subjects: 27955
Study: 28303471

Group type: EXPERIMENTAL
Intervention: Neutral pH bleaching gel (Pola Office+)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Acid pH bleaching gel (Pola Office)
Number of subjects: 54
Study: 25882604

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction for Breast Cancer (MBSR(BC)) program
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 72
Study: 24149738

Group type: EXPERIMENTAL
Intervention: 300 mg·d(‐1) magnesium oxide supplementation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 22047450

Group type: EXPERIMENTAL
Intervention: Diskus (fluticasone; D-group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Turbuhaler (budesonide; T-group)
Number of subjects: 100
Study: 19568054

Group type: EXPERIMENTAL
Intervention: Absorbable dermal stapler
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dermal sutures
Number of subjects: 11
Study: 17908741

Group type: EXPERIMENTAL
Intervention: Combined vitamin A and zinc supplement
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Zinc alone
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Vitamin A alone
Number of subjects: 707

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 707
Study: 14726116

Group type: EXPERIMENTAL
Intervention: Controlled Release (CR) tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Immediate Release (IR) tablets
Number of subjects: 12
Study: 11159302

Group type: EXPERIMENTAL
Intervention: 100 microgram salbutamol with non-electrostatic spacers
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 400 microgram salbutamol with non-electrostatic spacers
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 100 microgram salbutamol with Nebuchamber, Aerochamber, and Volumatic
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 400 microgram salbutamol with Nebuchamber, Aerochamber, and Volumatic
Number of subjects: 90
Study: 9563212

Group type: EXPERIMENTAL
Intervention: Pulsing electromagnetic fields (1 hour per day, 5 days per week)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Real pulsing electromagnetic fields (2 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo pulsing electromagnetic fields (2 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Half-power pulsing electromagnetic fields
Number of subjects: 23
Study: 7836491

Group type: EXPERIMENTAL
Intervention: High phenylalanine levels (Phe-level)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low phenylalanine levels (Phe-level)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (20 healthy subjects, mean age 20.7 years)
Number of subjects: 19
Study: 3407601

Group type: EXPERIMENTAL
Intervention: High-calorie meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-calorie meal
Number of subjects: 10
Study: 31319883

Group type: EXPERIMENTAL
Intervention: Lertal Group (LG)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Observation Group (OG)
Number of subjects: 128
Study: 28757571

Group type: EXPERIMENTAL
Intervention: Geophysical model function (GMF) and polarization ratio (PR) model for wind retrieval
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison with ECMWF re-analysis winds
Number of subjects: 16
Study: 26145837

Group type: EXPERIMENTAL
Intervention: CEH‐EUS‐FNA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional EUS‐FNA
Number of subjects: 40
Study: 23635551

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 23
Study: 21181180

Group type: EXPERIMENTAL
Intervention: Metric view (photograph of the lesion with a surgical ruler)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Frontal view
Number of subjects: 30

Group type: COMPARATOR
Intervention: Close-up view
Number of subjects: 30
Study: 19584772

Group type: EXPERIMENTAL
Intervention: Dysport (50, 60, or 70 units for women; 60, 70, or 80 units for men)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dysport
Number of subjects: 0
Study: 16647933

Group type: EXPERIMENTAL
Intervention: Pessary treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Vaginal reconstructive surgery
Number of subjects: 106

Group type: COMPARATOR
Intervention: Surgery group vs Pessary group
Number of subjects: 106
Study: 15262632

Group type: EXPERIMENTAL
Intervention: Closed kinetic chain exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open kinetic chain exercises
Number of subjects: 60
Study: 11331213

Group type: EXPERIMENTAL
Intervention: l‐T4 administration (100 microg/day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 9330779

Group type: EXPERIMENTAL
Intervention: BMS‐181101 under fasted conditions (days 1-6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BMS‐181101 under fed conditions (days 7-12)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BMS‐181101 administered with food
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BMS‐181101 administered without food
Number of subjects: 12
Study: 7970996

Group type: EXPERIMENTAL
Intervention: 5 mg/kg intravenous allopurinol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg/kg intravenous allopurinol
Number of subjects: 12
Study: 2912911

Group type: EXPERIMENTAL
Intervention: Panretinal (scatter) photocoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment density (repeating photocoagulation)
Number of subjects: 0
Study: 238810

Group type: EXPERIMENTAL
Intervention: Loxapine succinate (LOX) 40-65 mg/day, b.i.d. schedule
Number of subjects: 49

Group type: COMPARATOR
Intervention: Trifluoperazine hydrochloride (TFP) appropriate dosage
Number of subjects: 49
Study: 30950955

Group type: EXPERIMENTAL
Intervention: 3D separating, fusing, opacifying, false-coloring, and volume rendering (SFOF-VR) technique
Number of subjects: 109
Study: 28478093

Group type: EXPERIMENTAL
Intervention: DAK
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 26719316

Group type: EXPERIMENTAL
Intervention: Community-based WASH programme integrated with periodic mass distribution of albendazole every 6 months.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Mass deworming (albendazole) alone every 6 months.
Number of subjects: 18
Study: 24090384

Group type: EXPERIMENTAL
Intervention: Magnesium orotate and other antihypertensive, metabolic drugs, sedative and uroseptic phytotherapy, and nondrug measures
Number of subjects: 150
Study: 21355153

Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture combined with conventional acupuncture
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 80
Study: 19487705

Group type: EXPERIMENTAL
Intervention: Healthy Families America model prenatal intervention
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group (not exposed to the intervention)
Number of subjects: 238
Study: 17144787

Group type: EXPERIMENTAL
Intervention: Complementary medicine (including acupuncture, aromatherapy, massage, homeopathy, meditation, reflexology, herbal medicine, yoga, dietary supplements, relaxation techniques)
Number of subjects: 0
Study: 15686716

Group type: EXPERIMENTAL
Intervention: Steroid weaning
Number of subjects: 41
Study: 10971089

Group type: EXPERIMENTAL
Intervention: Transvaginal sonography (TVS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saline infusion sonohysterography (SIS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histological investigation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hysteroscopic control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less invasive biopsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fractionated curettage
Number of subjects: 0
Study: 8783703

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg b.i.d. for 5 days)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and Placebo
Number of subjects: 173
Study: 1454349

Group type: EXPERIMENTAL
Intervention: Pharmacologic mydriasis of the right eye
Number of subjects: 15
Study: 6508263

Group type: EXPERIMENTAL
Intervention: Timentin (ticarcillin plus clavulanic acid)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Comparative agents (piperacillin or moxalactam)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Moxalactam
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Timentin
Number of subjects: 116
Study: 31157962

Group type: EXPERIMENTAL
Intervention: Endocrine therapy (tamoxifen alone)
Number of subjects: 9427

Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy
Number of subjects: 9427
Study: 28724815

Group type: EXPERIMENTAL
Intervention: Intracameral mydriatic solution
Number of subjects: 127

Group type: COMPARATOR
Intervention: Topical mydriatics
Number of subjects: 127
Study: 27033859

Group type: EXPERIMENTAL
Intervention: BIOSCIENCE trial participants
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Non-participants from the CARDIOBASE registry
Number of subjects: 1216
Study: 25078879

Group type: EXPERIMENTAL
Intervention: Induced hypothermia at 33°C (n = 11)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Induced hypothermia at 36°C (n = 9)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 22999400

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of 10mg of 0.5% hyperbaric bupivacaine combined with 80 mcg of morphine and 2.5 mcg of sufentanil
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group receiving 10mg of 0.5% hyperbaric bupivacaine combined with 80 mcg of morphine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 19398784

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Danaproid sodium
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control
Number of subjects: 175
Study: 17488312

Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/kg (Group K1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg/kg (Group K2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propofol 3 mg/kg (Group P)
Number of subjects: 120
Study: 15034949

Group type: EXPERIMENTAL
Intervention: Benznidazole (BZ) with Thioctic Acid (TA) at daily doses of 50 to 100 mg for 30 days
Number of subjects: 249

Group type: COMPARATOR
Intervention: Benznidazole (BZ)
Number of subjects: 249
Study: 11062321

Group type: EXPERIMENTAL
Intervention: Categorized objects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral object
Number of subjects: 0
Study: 9630294

Group type: EXPERIMENTAL
Intervention: Full standardized dose of laser (40 x 1500 mW for 1500 ms)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Half standardized dose of laser (40 x 750 mW for 1500 ms)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Full treatment subgroup with neovascular glaucoma
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sighted eyes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Blind eyes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Postoperative inflammation
Number of subjects: 30
Study: 7983235

Group type: EXPERIMENTAL
Intervention: Nifedipine 50 mg once a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine retard 20 mg twice a day
Number of subjects: 0
Study: 2512486

Group type: EXPERIMENTAL
Intervention: Isocaloric protein‐restricted diet (0.4 g of protein per kilogram of body weight per day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Protein‐restricted diet
Number of subjects: 64
Study: 30596538

Group type: EXPERIMENTAL
Intervention: Health Information Package Program (HIPP) - video presentation and PowerPoint slides
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care in antenatal clinics (including iron supplementation)
Number of subjects: 200
Study: 28104250

Group type: EXPERIMENTAL
Intervention: Daclizumab 150mg subcutaneous every 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon beta-1a 30mcg intramuscular once weekly
Number of subjects: 0
Study: 26113419

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 73
Study: 22765642

Group type: EXPERIMENTAL
Intervention: Stainless steel brackets
Number of subjects: 32

Group type: COMPARATOR
Intervention: Esthetic brackets
Number of subjects: 32
Study: 21777736

Group type: EXPERIMENTAL
Intervention: Topical application of fipronil, amitraz and (S)-methoprene (CERTIFECT™) at 28 days prior to tick infestation.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Topical application of fipronil, amitraz and (S)-methoprene (CERTIFECT™) at 21 days prior to tick infestation.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Topical application of fipronil, amitraz and (S)-methoprene (CERTIFECT™) at 14 days prior to tick infestation.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not treated).
Number of subjects: 32
Study: 19433838

Group type: EXPERIMENTAL
Intervention: Multimodal cancer screening (including CA-125 tests, transvaginal sonograms, chest radiographs, flexible sigmoidoscopies, digital rectal examinations, and serum PSA tests)
Number of subjects: 68436

Group type: EXPERIMENTAL
Intervention: Multimodal cancer screening
Number of subjects: 68436
Study: 16618834

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 12510011

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 120
Study: 11045914

Group type: EXPERIMENTAL
Intervention: Low-dose PGE1 (2.5 - 5.0 microg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard sex therapy for twelve weeks
Number of subjects: 50
Study: 9200991

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 1552056

Group type: EXPERIMENTAL
Intervention: Tretinoin emollient cream 0.05%
Number of subjects: 296

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Tretinoin emollient cream 0.01%
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Tretinoin emollient cream 0.001%
Number of subjects: 296
Study: 3886304

Group type: EXPERIMENTAL
Intervention: 12 mg brompheniramine maleate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1 mg clemastine fumarate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29401075

Group type: EXPERIMENTAL
Intervention: Gum Elastic Bougie (GEB)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine intubation without GEB
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: GEB
Number of subjects: 110
Study: 27363400

Group type: EXPERIMENTAL
Intervention: Tailored patient-activation DXA result letter and educational brochure
Number of subjects: 7749

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 7749
Study: 25345961

Group type: EXPERIMENTAL
Intervention: Right ventricular apical (RVA) pacing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Right ventricular outflow tract (RVOT) pacing
Number of subjects: 60
Study: 24354588

Group type: COMPARATOR
Intervention: 13-valent conjugated pneumococcal vaccine
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Healthcare and non-healthcare resources use, quality-of-life (using EQ-5D and SF-36 questionnaires)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Out-of-pocket costs of patients and productivity losses of both patients and their caregivers
Number of subjects: 600
Study: 20090057

Group type: EXPERIMENTAL
Intervention: Anticipatory and Preventive Team Care (APTCare)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Usual care from family physicians
Number of subjects: 152
Study: 18947290

Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP) - Transbond Plus
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional two-step etch and primer method (CM) - Transbond XT
Number of subjects: 39

Group type: COMPARATOR
Intervention: Comparison of bonding procedures
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Type of tooth (incisor, canine, premolar)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Upper and lower dental arches
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Patients' gender
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Adhesive Remnant Index (ARI) scores
Number of subjects: 39
Study: 17444097

Group type: EXPERIMENTAL
Intervention: Microincision cataract surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Small incision cataract surgery
Number of subjects: 60
Study: 14672301

Group type: EXPERIMENTAL
Intervention: Community-based dietary diversification/modification intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diets
Number of subjects: 0
Study: 10090927

Group type: EXPERIMENTAL
Intervention: Busulfan 16 mg/kg
Number of subjects: 167

Group type: COMPARATOR
Intervention: Total Body Irradiation (TBI)
Number of subjects: 167
Study: 7884425

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2 intravenously over 1 hour every 3 weeks)
Number of subjects: 44